5th INTERNATIONAL CONFERENCE
ACUTE MYELOID LEUKEMIA "MOLECULAR AND TRANSLATIONAL": ADVANCES IN BIOLOGY AND TREATMENT

Estoril, Portugal
October 24-26, 2019

Chairs: Bob Löwenberg, Hartmut Döhner, Martin Tallman

Thursday, October 24, 2019

08:30–08:40 **Welcome**
Bob Löwenberg (Rotterdam), Hartmut Döhner (Ulm)

SESSION I - LEUKEMIA STEM CELLS
Chairs: David Scadden (Boston), Ivo Touw (Rotterdam)

08:40-08:55	Stem cells in human AML	Ravi Majeti (Stanford)
08:55-09:00	*Discussion*	
09:00-09:15	Absence of NKG2D ligands defines leukemia stem cells and mediates their immune evasion	Andreas Trumpp (Heidelberg)
09:15-09:20	*Discussion*	
09:20-09:35	Therapeutic targeting AML stem cells	Kolja Eppert (Montreal)
09:35-09:40	*Discussion*	
09:40-10:10	*Panel discussion*	

10:10-10:40 ***Coffee Break***

SESSION II - CLONAL HEMATOPOIESIS AND CLONAL DIVERSITY
Chairs: Ravi Majeti (Stanford), Andreas Trumpp (Heidelberg)

10:40-10:55	The biological and clinical impact of clonal hematopoiesis	Siddhartha Jaiswal (Stanford)
10:55-11:00	*Discussion*	
11:00-11:15	Clonal hematopoiesis: predicting development of AML	Liran Shlush (Rehovot)
11:15-11:20	*Discussion*	
11:20-11:35	Immortal HSCs and their regulation by DNA methylation	Peggy Goodell (Houston)
11:35-11:40	*Discussion*	
11:40-12:10	*Panel discussion*	

12:10-13:50 Lunch

12:40-13:40 3 Simultaneous Meet the Expert Sessions

1. Treatment of molecular subsets of AML	Eytan Stein (New York)
2. Introducing novel drugs in our current treatment algorithm of AML	Andrew Wei (Melbourne)
3. Taking advantage of MRD assessment in clinical practice	Gert Ossenkoppele (Amsterdam)

12:40-13:40 **SATELLITE SYMPOSIUM:**
AML Treatment in 2019: Where Are We Now and Where Are We Headed?
Speakers: Konstanze Döhner (Ulm), Amer Zeidan (New Haven)

This symposium is organized and funded by Novartis

SESSION III - GENETICS AND EPIGENETICS
Chairs: Scott Armstrong (Boston), Peggy Goodell (Houston)

13:50-14:05	The AML genome(s) and epigenome(s)	Lars Bullinger (Berlin)
14:05-14:10	*Discussion*	
14:10-14:25	Enhancer and 3D genome remodelling in the induction and maintenance of leukemia	Brian Huntly (Cambridge)
14:25-14:30	*Discussion*	
14:30-14:45	Molecular breakdown of EVI1-AML	Ruud Delwel (Rotterdam)
14:45-14:50	*Discussion*	
14:50 -15:05	The role of MBD4 in AML development	Ian Majewski (Melbourne)
15:05-15:10	*Discussion*	
15:10-15:40	*Panel discussion*	

15:40-16:10 Coffee break

SESSION IV - PRELEUKEMIC CONDITIONS
Chairs: Siddhartha Jaiswal (Stanford), Ruud Delwel (Rotterdam)

16:10-16:25	Molecular mechanisms driving malignant transformation of severe congenital neutropenia	Ivo Touw (Rotterdam)
16:25-16:30	*Discussion*	
16:30-16:45	Inherited bone marrow failure as a preleukemic condition	Jean Soulier (Paris)
16:45-16:50	*Discussion*	
16:50-17:05	Marrow failure and AML	Akiko Shimamura (Boston)
17:05-17:10	*Discussion*	

17:10-17:25	Mechanisms of progression of the MPNs to AML	John Crispino (Chicago)
17:25-17:30	*Discussion*	
17:30-17:45	Recognition of patients with germline susceptibility to myeloid malignancies	Lucy Godley (Chicago)
17:45-17:50	*Discussion*	
17:50-18:20	*Panel discussion*	

18:20-20:00 **On-Site Get-Together and Poster Walk (Cocktails and stand up buffet dinner for all)**

Friday, October 25, 2019

08:00-09:00 **SATELLITE SYMPOSIUM:**
The enigma of high-risk AML*
***High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)**
Speakers: Lars Bullinger (Berlin), Donald McLornan (London)

This promotional symposium is funded and organized by Jazz Pharmaceuticals

SESSION V: MOLECULAR THERAPEUTICS I
Chairs: John Crispino (Chicago), Marina Konopleva (Houston)

09:15-09:30	Identification of new AML targets with CRISPR-based approaches	Kimberley Stegmaier (Boston)
09:30-09:35	*Discussion*	
09:35-09:50	MLL-Menin inhibition reverses pre-leukemic progenitor self-renewal induced by NPM1 mutations.	Scott Armstrong (Boston)
09:50-09:55	*Discussion*	
09:55-10:10	Bcl-2/Mcl-1 targeting (translational aspects)	Andrew Roberts (Melbourne)
10:10-10:15	*Discussion*	
10:15-10:30	Targeting RUNX1	Guy Sauvageau (Montreal)
10:30-10:35	*Discussion*	
10:35-11:05	*Panel discussion*	

11:05-11:35 ***Coffee break***

SESSION VI: BIOLOGY OF MINIMAL RESIDUAL DISEASE
Chairs: John DiPersio (Saint-Louis), Liran Shlush (Rehovot)

11:35-11:50	NGS-based molecular minimal residual disease detection in AML	Peter Valk (Rotterdam)
11:50-11:55	*Discussion*	

11:55-12:10	Single cell MRD in AML	Paresh Vyas (Oxford)
12:10-12:15	*Discussion*	
12:15-12:30	Flow cytometric MRD	Jacqueline Cloos (Amsterdam)
12:30-12:35	*Discussion*	
12:35-13:05	*Panel discussion*	

13:05-14:45 ***Lunch***

13:35-14:35 **3 Simultaneous Meet the Expert Sessions**

1. Integrating molecular diagnostics in clinical management — Peter Valk (Rotterdam)
2. Treatment of the older patient with AML — Hartmut Döhner (Ulm)
3. Trial design — Bob Löwenberg (Rotterdam)

13:35-14:35 **SATELLITE SYMPOSIUM:**
Expert insights on the rapidly evolving FLT3-positive AML treatment landscape
Chair: Paresh Vyas (Oxford)
Speakers: Naval Daver (Houston), Konstanze Döhner (Ulm)

This symposium is organized and funded by Daiichi Sankyo Europe GmbH

SESSION VII: IMMUNOTHERAPEUTIC TARGETING
Chairs: Gert Ossenkoppele (Amsterdam), Andrew Wei (Melbourne)

14:45-15:00	Targeting AML with CAR-T cells	Silvia Arcangeli (Milan)
15:00-15:05	*Discussion*	
15:05-15:20	CD123 DARTS, BITES, antibodies and ADCs for the treatment of AML	John DiPersio (Saint-Louis)
15:20-15:25	*Discussion*	
15:25-15:40	Immune targeting of tumor necrosis factor receptors/CD70 in leukemia	Adrian Ochsenbein (Bern)
15:40-15:45	*Discussion*	
15:45-16:00	Therapeutic targeting of the macrophage immune checkpoint CD47 in AML	Ravi Majeti (Stanford)
16:00-16:05	*Discussion*	
16:05-16:35	*Panel discussion*	

16:35-17:05 ***Coffee Break***

SESSION VIII: MOLECULAR THERAPEUTICS II
Chairs: Andrew Roberts (Melbourne), Eytan Stein (New York)

17:05-17:20	Clinical use of FLT3 inhibitors	Alexander Perl (Philadelphia)
17:20-17:25	*Discussion*	
17:25-17:40	FLT3 internal tandem duplication regulates EZH2 expression and myeloid maturation	Martin Carroll (Philadelphia)
17:40-17:45	*Discussion*	
17:45-18:00	Discovering novel therapeutic targets in AML	Ross Levine (New York)
18:00-18:05	*Discussion*	
18:05-18:20	FLT3 inhibitor therapeutic combinations	Catherine Smith (San Francisco)
18:20-18:25	*Discussion*	
18:25-18:55	*Panel discussion*	

Free evening

Saturday, October 26, 2019

SESSION IX: MOLECULAR THERAPEUTICS III
Chairs: Hartmut Döhner (Ulm), Bob Löwenberg (Rotterdam)

09:15-09:30	MDM2 P53 targeting	Marina Konopleva (Houston)
09:30-09:35	*Discussion*	
09:35-09:50	Clinical developments of Bcl-2/Mcl-1 targeting in AML	Andrew Wei (Melbourne)
09:50-09:55	*Discussion*	
09:55-10:10	Proton shifting induces cell growth and is exploited in AML	David Scadden (Boston)
10:10-10:15	*Discussion*	
10:15-10:30	Targeting IDH1/IDH2	Eytan Stein (New York)
10:30-10:35	*Discussion*	
10:35-11:05	*Panel discussion*	
11:05-11:15	***Closing remarks***	

MEETING CLOSURE